FGFR3 and urinary bladder carcinoma: In 2019, the FDA approved Erdafitinib as a treatment for locally advanced or metastatic bladder cancer with susceptible FGFR2 or FGFR3 alterations, making a profound advancement in treatment for the FGFR-altered subset of bladder cancer [9].